Fluicell AB (FLUI) - Net Assets
Based on the latest financial reports, Fluicell AB (FLUI) has net assets worth Skr14.21 Million SEK (≈ $1.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr20.77 Million ≈ $2.23 Million USD) and total liabilities (Skr6.56 Million ≈ $705.64K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Fluicell AB to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr14.21 Million |
| % of Total Assets | 68.43% |
| Annual Growth Rate | 22.33% |
| 5-Year Change | -42.96% |
| 10-Year Change | 492.12% |
| Growth Volatility | 1262.7 |
Fluicell AB - Net Assets Trend (2014–2025)
This chart illustrates how Fluicell AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Fluicell AB.
Annual Net Assets for Fluicell AB (2014–2025)
The table below shows the annual net assets of Fluicell AB from 2014 to 2025. Also explore FLUI shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr10.90 Million ≈ $1.17 Million |
-43.32% |
| 2024-12-31 | Skr19.23 Million ≈ $2.07 Million |
+4425.65% |
| 2023-12-31 | Skr425.00K ≈ $45.74K |
-98.19% |
| 2022-12-31 | Skr23.45 Million ≈ $2.52 Million |
+22.68% |
| 2021-12-31 | Skr19.11 Million ≈ $2.06 Million |
-1.98% |
| 2020-12-31 | Skr19.50 Million ≈ $2.10 Million |
+90.69% |
| 2019-12-31 | Skr10.22 Million ≈ $1.10 Million |
-56.25% |
| 2018-12-31 | Skr23.37 Million ≈ $2.52 Million |
+143.93% |
| 2017-12-31 | Skr9.58 Million ≈ $1.03 Million |
+420.48% |
| 2016-12-31 | Skr1.84 Million ≈ $198.12K |
+165.27% |
| 2015-12-31 | Skr694.00K ≈ $74.69K |
-41.54% |
| 2014-12-31 | Skr1.19 Million ≈ $127.76K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Fluicell AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13462905000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.75 Million | 25.20% |
| Other Comprehensive Income | Skr10.34 Million | 94.82% |
| Other Components | Skr134.71 Million | 1235.76% |
| Total Equity | Skr10.90 Million | 100.00% |
Fluicell AB Competitors by Market Cap
The table below lists competitors of Fluicell AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nicoccino Holding AB
ST:NICO
|
$4.65 Million |
|
NedSense Enterprises NV
AS:NEDSE
|
$4.65 Million |
|
C&C Group plc
LSE:CCR
|
$4.65 Million |
|
Austin Metals Ltd
AU:AYT
|
$4.65 Million |
|
Nandani Creation Limited
NSE:JAIPURKURT
|
$4.64 Million |
|
Belmont Resources Inc
V:BEA
|
$4.64 Million |
|
CCH Holdings Ltd Ordinary Shares
NASDAQ:CCHH
|
$4.63 Million |
|
Ambica Agarbathies & Aroma industries Limited
NSE:AMBICAAGAR
|
$4.62 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fluicell AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,234,000 to 10,901,000, a change of -8,333,000 (-43.3%).
- Net loss of 8,332,000 reduced equity.
- Other comprehensive income increased equity by 6,846,000.
- Other factors decreased equity by 6,847,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.33 Million | -76.43% |
| Other Comprehensive Income | Skr6.85 Million | +62.8% |
| Other Changes | Skr-6.85 Million | -62.81% |
| Total Change | Skr- | -43.32% |
Book Value vs Market Value Analysis
This analysis compares Fluicell AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 234.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.47x to 234.12x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr9.05 | Skr31.40 | x |
| 2015-12-31 | Skr5.29 | Skr31.40 | x |
| 2016-12-31 | Skr14.03 | Skr31.40 | x |
| 2017-12-31 | Skr46.00 | Skr31.40 | x |
| 2018-12-31 | Skr84.20 | Skr31.40 | x |
| 2019-12-31 | Skr34.15 | Skr31.40 | x |
| 2020-12-31 | Skr0.35 | Skr31.40 | x |
| 2021-12-31 | Skr0.32 | Skr31.40 | x |
| 2022-12-31 | Skr0.35 | Skr31.40 | x |
| 2023-12-31 | Skr0.41 | Skr31.40 | x |
| 2024-12-31 | Skr16.25 | Skr31.40 | x |
| 2025-12-31 | Skr0.13 | Skr31.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fluicell AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -138.82%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.69x
- Recent ROE (-76.43%) is above the historical average (-664.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -138.73% | -1174.10% | 0.08x | 1.41x | Skr-1.77 Million |
| 2015 | -545.16% | -267.23% | 0.83x | 2.46x | Skr-3.85 Million |
| 2016 | -268.88% | -187.86% | 0.95x | 1.51x | Skr-5.13 Million |
| 2017 | -77.96% | -710.08% | 0.09x | 1.20x | Skr-8.43 Million |
| 2018 | -62.89% | -1199.02% | 0.05x | 1.11x | Skr-17.04 Million |
| 2019 | -182.25% | -749.00% | 0.12x | 1.95x | Skr-19.66 Million |
| 2020 | -93.11% | -391.67% | 0.19x | 1.27x | Skr-20.10 Million |
| 2021 | -113.65% | -834.74% | 0.10x | 1.41x | Skr-23.63 Million |
| 2022 | -91.64% | -660.94% | 0.10x | 1.35x | Skr-23.83 Million |
| 2023 | -6248.00% | -795.51% | 0.36x | 21.98x | Skr-26.60 Million |
| 2024 | -80.64% | -834.37% | 0.07x | 1.33x | Skr-17.43 Million |
| 2025 | -76.43% | -138.82% | 0.32x | 1.69x | Skr-9.42 Million |
Industry Comparison
This section compares Fluicell AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,474,578
- Average return on equity (ROE) among peers: -114.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fluicell AB (FLUI) | Skr14.21 Million | -138.73% | 0.46x | $4.64 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $8.55 Million |
| AcouSort AB (ACOU) | $8.46 Million | -178.16% | 0.46x | $6.79 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $12.40 Million |
| Alzinova AB (ALZ) | $947.42K | -195.83% | 0.18x | $9.77 Million |
| AlzeCure Pharma (ALZCUR) | $60.48 Million | -92.65% | 0.17x | $95.72 Million |
| Annexin Pharmaceuticals AB (ANNX) | $2.71 Million | -51.19% | 0.36x | $9.14 Million |
| Alligator Bioscience AB (ATORX) | $115.24 Million | -124.61% | 0.32x | $2.29 Million |
| BioInvent International AB (BINV) | $55.63 Million | -317.55% | 1.27x | $158.27 Million |
| BioArctic AB (publ) (BIOA-B) | $974.50 Million | 9.08% | 0.21x | $2.57 Billion |
About Fluicell AB
Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve sys… Read more